Pipeline

October 8, 2018

Company	Drug/Device	Medical Condition	Status
Paratek Pharmaceuticals, Inc.	SEYSARA™ (sarecycline)	Inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older	Granted approval by the FDA
Clovis Oncology, Inc.	Rubraca® (rucaparib)	BRCA1/2-mutated mCRPC after androgen receptor (AR)-directed therapy and taxane-based chemotherapy	Granted Breakthrough Therapy designation by the FDA
PharmAbcine, Inc.	Bevacizumab (Avastin®)	Recurrent glioblastoma	Received “Study May Proceed Letter “ for IND application from the FDA; can initiate Phase II trials
Amgen	KYPROLIS® (carfilzomib)	Relapsed or refractory multiple myeloma	FDA approved supplemental New Drug Application to expand prescribing information
Applied BioCode	BioCode® Gastrointestinal Pathogen Panel on BioCode® MDx-3000 molecular system	Tests for 17 most common bacteria, viruses and parasites that cause infectious diarrhea	Granted 510 (k) clearance by the FDA
Eisai Co., Ltd.	Fycompa (perampanel)	Partial-onset seizures in pediatric patients with epilepsy 4 years of age and older	Granted approval by the FDA for an indication expansion
Eli Lilly and Company	Ultra Rapid Lispro (URLi)	Type 1 and Type 2 diabetes	Phase III clinical trials show met primary efficacy endpoint
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited	ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone)	CD30-expressing peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma (MTCL)	Phase III ECHELON-2 clinical trial met its primary endpoint
Acorda Therapeutics, Inc.	INBRIJA, investigational inhaled levodopa	OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen	Releasing efficacy analysis from SPAN-PD, Phase III clinical trial
Five Prime Therapeutics, Inc.	Bemarituzumab (FPA144), an isoform-selective FGF receptor 2b (FGFR2b) antibody, with chemotherapy	Advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer	First patient dosed in Phase III FIGHT pivotal trial
Ocugen, Inc.	OCU310	Dry eye	Initiated Phase III clinical trial
PTC Therapeutics	Risdiplam (RG7916)	Type 1, 2 and 3 spinal muscular atrophy (SMA)	Interim data from open-label clinical trials show increases in developmental motor milestones
Veloce BioPharma, LLC	VBP-926 (Povidone-Iodine) topical treatment	Chemo-associated paronychia, or painful, inflamed nails, a chemo side effect	Positive results of Phase IIb trial